Honghong Zhou

发表

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

D. Montefiori, S. Chalkias, F. Dutko, 2022, medRxiv.

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

D. Montefiori, J. Tomassini, S. Swaminathan, 2022, The Journal of infectious diseases.

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Lindsay N. Carpp, M. Andrasik, J. Kublin, 2021, Science.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

J. Mascola, D. Montefiori, N. Sullivan, 2022, The New England journal of medicine.

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

D. Montefiori, J. Tomassini, A. Atz, 2022, The New England journal of medicine.

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

D. Follmann, K. Neuzil, M. Desjardins, 2022, Annals of Internal Medicine.

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

J. Tomassini, J. Nayak, G. Fuchs, 2022, The New England journal of medicine.

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

D. Montefiori, J. Tomassini, S. Chalkias, 2022, The New England journal of medicine.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

J. Mascola, D. Follmann, S. Spector, 2020, The New England journal of medicine.

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

R. Pajon, Jacqueline M. Miller, Kashif Ali, 2021, The New England journal of medicine.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

J. Mascola, C. Fichtenbaum, D. Follmann, 2021, The New England journal of medicine.

Associations of Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA-1273 Vaccine in COVE and TeenCOVE Trials.

J. Tomassini, Avika Dixit, L. Baden, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Lindsay N. Carpp, M. Andrasik, J. Kublin, 2021, medRxiv.

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

D. Montefiori, S. Chalkias, L. Baden, 2022, Nature Medicine.

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children

D. Montefiori, J. Tomassini, R. Pajon, 2022, medRxiv.

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

D. Follmann, J. Tomassini, K. Neuzil, 2021, The New England journal of medicine.

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination

D. Montefiori, J. Tomassini, J. Marshall, 2022, The New England journal of medicine.

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Lindsay N. Carpp, M. Fay, T. Fleming, 2020, Annals of Internal Medicine.

A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.

S. Weaver, C. Shaw, T. Brasel, 2023, Vaccine.

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

E. Kerwin, J. Tomassini, L. Baden, 2022, Nature Medicine.

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Lindsay N. Carpp, M. Andrasik, J. Kublin, 2023, Science Translational Medicine.

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

P. Dargan, J. Tomassini, P. Kalra, 2023, The Lancet Infectious Diseases.

A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

Lindsay N. Carpp, M. Fay, J. Kublin, 2021, Annals of Internal Medicine.

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

Lindsay N. Carpp, M. Fay, J. Kublin, 2020, medRxiv.

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

E. Kerwin, J. Tomassini, I. Frank, 2021, medRxiv.

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination

D. Montefiori, J. Tomassini, S. Chalkias, 2022, New England Journal of Medicine.

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

D. Montefiori, J. Tomassini, S. Chalkias, 2023, Nature Medicine.

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

D. Montefiori, J. Tomassini, S. Chalkias, 2023, Nature communications.

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary Report

A. Carfi, R. Pajon, A. Choi, 2022, medRxiv.

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

D. Montefiori, J. Tomassini, A. Atz, 2022, The New England Journal of Medicine.

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial

C. Griffin, Honghong Zhou, B. Girard, 2024, The Lancet Infectious Diseases.